Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.52 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.52 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1419600 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL5240928 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL29270787 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL6170645 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL431541 | 0.94 | HTT (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9874334 | 0.92 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9340146 | 0.92 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15346534 | 0.92 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL18254066 | 0.91 | HTT (0.81) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL6447301 | 0.88 | HTT (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107106709-B | Radiopharmaceutical conjugates comprising a metabolite and an EPR agent targeting tumor cells | 南非核能源有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| WO-2016046793-A2 | RADIOPHARMACEUTICAL CONJUGATE | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | HTT 3013/4885TGM2 456/4885LMNA 1765/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | HTT 3083/4885TGM2 561/4885LMNA 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.